The European Medicines Agency is set to decide this week whether to recommend pan-EU marketing approval for a number of new products, including concizumab, Novo Nordisk’s drug for hemophilia A and B that was resubmitted for regulatory review in the US in June after being rejected there last year.
EU Decision Time For Hemophilia Drug Concizumab & 10 Other Products
Concizumab sponsor Novo Nordisk and a number of other companies could soon learn whether or not the European Medicines Agency will give their respective drugs the marketing thumbs up.
